New Insights and Implications of Natural Killer Cells in Parkinson's Disease
- PMID: 35570499
- PMCID: PMC9535577
- DOI: 10.3233/JPD-223212
New Insights and Implications of Natural Killer Cells in Parkinson's Disease
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease and is characterized by the loss of dopaminergic neurons in the substantia nigra and the abnormal aggregation and accumulation of the alpha-synuclein (α-syn) protein into Lewy bodies. It is established that there is an association between inflammation and PD; however, the time course of the inflammatory process as well as the immune cells involved are still debated. Natural killer (NK) cells are innate lymphocytes with numerous functions including targeting and killing infected or malignant cells, antimicrobial defense, and resolving inflammation. NK cell subsets differ in their effector function capacities which are modulated by activating and inhibitory receptors expressed at the cell surface. Alterations in NK cell numbers and receptor expression have been reported in PD patients. Recently, NK cell numbers and frequency were shown to be altered in the periphery and in the central nervous system in a preclinical mouse model of PD. Moreover, NK cells have recently been shown to internalize and degrade α-syn aggregates and systemic NK cell depletion exacerbated synuclein pathology in a preclinical mouse model of PD, indicating a potential protective role of NK cells. Here, we review the inflammatory process in PD with a particular focus on alterations in NK cell numbers, phenotypes, and functions.
Keywords: NK cells; Parkinson’s disease; immune system; inflammation.
Conflict of interest statement
The authors have no conflict of interest to report.
Similar articles
-
NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1762-1771. doi: 10.1073/pnas.1909110117. Epub 2020 Jan 3. Proc Natl Acad Sci U S A. 2020. PMID: 31900358 Free PMC article.
-
The role of natural killer cells in Parkinson's disease.Exp Mol Med. 2020 Sep;52(9):1517-1525. doi: 10.1038/s12276-020-00505-7. Epub 2020 Sep 24. Exp Mol Med. 2020. PMID: 32973221 Free PMC article. Review.
-
Single-cell RNA sequencing of CSF reveals neuroprotective RAC1+ NK cells in Parkinson's disease.Front Immunol. 2022 Sep 21;13:992505. doi: 10.3389/fimmu.2022.992505. eCollection 2022. Front Immunol. 2022. PMID: 36211372 Free PMC article.
-
Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.Glia. 2018 Aug;66(8):1752-1762. doi: 10.1002/glia.23338. Epub 2018 Apr 6. Glia. 2018. PMID: 29624735
-
Pathological Role of Natural Killer Cells in Parkinson's Disease: A Systematic Review.Front Aging Neurosci. 2022 May 18;14:890816. doi: 10.3389/fnagi.2022.890816. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35663564 Free PMC article.
Cited by
-
Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson's disease patients.NPJ Parkinsons Dis. 2024 Feb 15;10(1):36. doi: 10.1038/s41531-024-00652-y. NPJ Parkinsons Dis. 2024. PMID: 38360903 Free PMC article.
-
The Peripheral Immune Traits Changed in Patients with Multiple System Atrophy.Brain Sci. 2023 Jan 26;13(2):205. doi: 10.3390/brainsci13020205. Brain Sci. 2023. PMID: 36831748 Free PMC article.
-
The role of CD56bright NK cells in neurodegenerative disorders.J Neuroinflammation. 2024 Feb 13;21(1):48. doi: 10.1186/s12974-024-03040-8. J Neuroinflammation. 2024. PMID: 38350967 Free PMC article. Review.
-
Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond.Curr Neuropharmacol. 2024;22(6):1080-1109. doi: 10.2174/1570159X22666231017141636. Curr Neuropharmacol. 2024. PMID: 37898823 Free PMC article.
-
The immune system in Parkinson's disease: what we know so far.Brain. 2024 Oct 3;147(10):3306-3324. doi: 10.1093/brain/awae177. Brain. 2024. PMID: 38833182 Free PMC article. Review.
References
-
- El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J 20, 419–425. - PubMed
-
- Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K (2006) The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J Neural Transm (Vienna) 113, 1435–1439. - PubMed
-
- Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG (2011) α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study. Lancet Neurol 10, 230–240. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous